This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 65.7 kDa.
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 575 nm
Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Flow Cytometry assay shows that PE-Labeled Human SIRP alpha, Fc Tag (Cat. No. SIA-HP252) can bind to Jurkat cells overexpressing human CD47. 1 μL stock solution per million cells (QC tested).
FACS analysis shows that the binding of PE-Labeled Human SIRP alpha, Fc Tag (Cat. No. SIA-HP252) to Jurkat cells overexpressing CD47 was inhibited by increasing concentration of neutralizing anti-human CD47 antibody. The IC50 is 0.37 μg/mL (QC tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $300.00
Price(USD) : $1050.00
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.